Abstract |
Migraine remains one of the most disabling disorders worldwide. The high prevalence in the general population and the often-delicate treatment of patients account for that. Therapeutic management of migraine relies mainly on non-specific medical treatment and is affected by low patient adherence to the treatment regimens applied. The introduction of specific anti- migraine treatment occurred over 20 years ago when the first triptan was approved by regulatory authorities ( sumatriptan, 28 December 1992). Triptan use is limited by side effects, time- and frequency-restricted application, and the risk of developing medication overuse headache. Within the past few years, new and promising drugs such as more specific 5-HT 1F receptor agonists (that is, lasmiditan) and monoclonal calcitonin gene-related peptide ( CGRP) receptor antibodies entered advanced development phases while non-invasive neuromodulatory approaches were suggested to be potentially effective as non- pharmaceutical interventions for migraine.
|
Authors | Mark Obermann, Dagny Holle |
Journal | F1000Research
(F1000Res)
Vol. 5
Pg. 2726
( 2016)
ISSN: 2046-1402 [Print] England |
PMID | 29098075
(Publication Type: Journal Article, Review)
|